Therapeutic targeting of macrophages in lupus nephritis

Samantha A. Chalmers, Violeta Chitu, Meera Ramanujam, Chaim Putterman

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Systemic lupus erythematosus (SLE) is an autoimmune disease which results in multiple different end organ pathologies, including the kidney. Lupus nephritis (LN) is one of the most serious complications of SLE, and a leading cause of morbidity and mortality. Current treatment options are suboptimal, involving non-specific immunosuppression which exposes patients to potentially serious side effects with no guarantee of remission. More targeted therapeutic approaches may improve treatment results. Many studies have implicated macrophages as actively contributing to LN pathogenesis in both human and murine disease. Indeed, various studies have shown that depletion of macrophage populations, inhibition of macrophage recruitment, and disruption of inflammatory macrophage activation and polarization have significantly ameliorated nephritis in several different murine LN models. The current literature explores targeting macrophages by several different means, including the CSF-1/CSF-1R signaling axis, the CX3CL1/CX3CR1 signaling axis, the CCL2/CCR2 signaling axis, and Bruton's tyrosine kinase (BTK), all of which hold promise as targets for future LN treatments. These studies highlight the potential benefit of targeting macrophages in LN, and emphasize the need for future investigations to discern the ideal mean(s) for targeting macrophages in LN.

Original languageEnglish (US)
Pages (from-to)43-49
Number of pages7
JournalDiscovery medicine
Volume20
Issue number108
StatePublished - 2015

Fingerprint

Lupus Nephritis
Macrophages
Systemic Lupus Erythematosus
Therapeutics
Macrophage Colony-Stimulating Factor
Macrophage Activation
Nephritis
Immunosuppression
Autoimmune Diseases
Pathology
Morbidity
Kidney
Mortality
Population

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Therapeutic targeting of macrophages in lupus nephritis. / Chalmers, Samantha A.; Chitu, Violeta; Ramanujam, Meera; Putterman, Chaim.

In: Discovery medicine, Vol. 20, No. 108, 2015, p. 43-49.

Research output: Contribution to journalArticle

Chalmers, SA, Chitu, V, Ramanujam, M & Putterman, C 2015, 'Therapeutic targeting of macrophages in lupus nephritis', Discovery medicine, vol. 20, no. 108, pp. 43-49.
Chalmers, Samantha A. ; Chitu, Violeta ; Ramanujam, Meera ; Putterman, Chaim. / Therapeutic targeting of macrophages in lupus nephritis. In: Discovery medicine. 2015 ; Vol. 20, No. 108. pp. 43-49.
@article{9bd7101260fa4adc9d8b72aab02e9483,
title = "Therapeutic targeting of macrophages in lupus nephritis",
abstract = "Systemic lupus erythematosus (SLE) is an autoimmune disease which results in multiple different end organ pathologies, including the kidney. Lupus nephritis (LN) is one of the most serious complications of SLE, and a leading cause of morbidity and mortality. Current treatment options are suboptimal, involving non-specific immunosuppression which exposes patients to potentially serious side effects with no guarantee of remission. More targeted therapeutic approaches may improve treatment results. Many studies have implicated macrophages as actively contributing to LN pathogenesis in both human and murine disease. Indeed, various studies have shown that depletion of macrophage populations, inhibition of macrophage recruitment, and disruption of inflammatory macrophage activation and polarization have significantly ameliorated nephritis in several different murine LN models. The current literature explores targeting macrophages by several different means, including the CSF-1/CSF-1R signaling axis, the CX3CL1/CX3CR1 signaling axis, the CCL2/CCR2 signaling axis, and Bruton's tyrosine kinase (BTK), all of which hold promise as targets for future LN treatments. These studies highlight the potential benefit of targeting macrophages in LN, and emphasize the need for future investigations to discern the ideal mean(s) for targeting macrophages in LN.",
author = "Chalmers, {Samantha A.} and Violeta Chitu and Meera Ramanujam and Chaim Putterman",
year = "2015",
language = "English (US)",
volume = "20",
pages = "43--49",
journal = "Discovery medicine",
issn = "1539-6509",
publisher = "Discovery Medicine",
number = "108",

}

TY - JOUR

T1 - Therapeutic targeting of macrophages in lupus nephritis

AU - Chalmers, Samantha A.

AU - Chitu, Violeta

AU - Ramanujam, Meera

AU - Putterman, Chaim

PY - 2015

Y1 - 2015

N2 - Systemic lupus erythematosus (SLE) is an autoimmune disease which results in multiple different end organ pathologies, including the kidney. Lupus nephritis (LN) is one of the most serious complications of SLE, and a leading cause of morbidity and mortality. Current treatment options are suboptimal, involving non-specific immunosuppression which exposes patients to potentially serious side effects with no guarantee of remission. More targeted therapeutic approaches may improve treatment results. Many studies have implicated macrophages as actively contributing to LN pathogenesis in both human and murine disease. Indeed, various studies have shown that depletion of macrophage populations, inhibition of macrophage recruitment, and disruption of inflammatory macrophage activation and polarization have significantly ameliorated nephritis in several different murine LN models. The current literature explores targeting macrophages by several different means, including the CSF-1/CSF-1R signaling axis, the CX3CL1/CX3CR1 signaling axis, the CCL2/CCR2 signaling axis, and Bruton's tyrosine kinase (BTK), all of which hold promise as targets for future LN treatments. These studies highlight the potential benefit of targeting macrophages in LN, and emphasize the need for future investigations to discern the ideal mean(s) for targeting macrophages in LN.

AB - Systemic lupus erythematosus (SLE) is an autoimmune disease which results in multiple different end organ pathologies, including the kidney. Lupus nephritis (LN) is one of the most serious complications of SLE, and a leading cause of morbidity and mortality. Current treatment options are suboptimal, involving non-specific immunosuppression which exposes patients to potentially serious side effects with no guarantee of remission. More targeted therapeutic approaches may improve treatment results. Many studies have implicated macrophages as actively contributing to LN pathogenesis in both human and murine disease. Indeed, various studies have shown that depletion of macrophage populations, inhibition of macrophage recruitment, and disruption of inflammatory macrophage activation and polarization have significantly ameliorated nephritis in several different murine LN models. The current literature explores targeting macrophages by several different means, including the CSF-1/CSF-1R signaling axis, the CX3CL1/CX3CR1 signaling axis, the CCL2/CCR2 signaling axis, and Bruton's tyrosine kinase (BTK), all of which hold promise as targets for future LN treatments. These studies highlight the potential benefit of targeting macrophages in LN, and emphasize the need for future investigations to discern the ideal mean(s) for targeting macrophages in LN.

UR - http://www.scopus.com/inward/record.url?scp=84940886543&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84940886543&partnerID=8YFLogxK

M3 - Article

C2 - 26321086

AN - SCOPUS:84940886543

VL - 20

SP - 43

EP - 49

JO - Discovery medicine

JF - Discovery medicine

SN - 1539-6509

IS - 108

ER -